Filing Details

  

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

 

Yubo International Biotech Limited

(Name of Issuer)

 

Class A Common Stock, $.001 par value

(Title of Class of Securities)

 

988366100

(CUSIP Number)

 

Boao Biotech Limited

Wickham’s Cay II, P.O. Box 2221

Road Town, Tortola, British Virgin Islands

(Name, Address, and Telephone Number of Person Authorized to Receive Notices and Communications)

 

With a copy to:

Mark C. Lee, Esq.

Greenberg Traurig, LLP

1201 K Street, Suite 1100

Sacramento, California 95814 

January 14, 2021

(Date of Event which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

 

Note:Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See §240.13d-7 for other parties to whom copies are to be sent.

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

  

CUSIP No. 988366100

Page 2 of 5

 

1	NAME OF REPORTING PERSON   Boao Biotech Limited
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)   (a) ☐ (b) ☐
3	SEC USE ONLY
4	SOURCE OF FUNDS (See Instructions)   WC
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)	☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION   British Virgin Islands

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER   24,967,800
		8	SHARED VOTING POWER   0
		9	SOLE DISPOSITIVE POWER   24,967,8001
		10	SHARED DISPOSITIVE POWER   0

 

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   24,967,800
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)	☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)   21.1%2
14	TYPE OF REPORTING PERSON (See Instructions)   OO

_____________ 

¹ Consists of 24,967,800 shares of Class A Common Stock directly held by Boao Biotech Limited.

² The percentage is based on 118,177,885 shares of Series A Common Stock outstanding on January 14, 2021.

 

 

 

CUSIP No. 988366100

Page 3 of 5

 

Item 1. Security and Issuer

 

This Schedule 13D relates to the shares of Class A Common Stock, $.001 par value per share (“Class A Common Stock”), of Yubo International Biotech Limited (the “Issuer”). The principal executive offices of the Issuer are located at Room 105, Building 5, Xishiku Avenue, Xicheng District, Beijing, China.

 

Item 2. Identity and Background

 

(a) This Schedule 13D is being filed by Boao Biotech Limited (the “Reporting Person”).

 

(b) The business address of Boao Biotech Limited is Wickham’s Cay II, P.O. Box 2221, Road Town, Tortola, British Virgin Islands.

 

(c) Boao Biotech Limited is an investment holding company.

 

(d) During the last five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

 

(e) During the last five years the Reporting Person was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws.

 

(f) Boao Biotech Limited is organized under the law of British Virgin Islands.

 

Item 3. Source and Amount of Funds or Other Consideration

 

The Reporting Person acquired 24,967,800 shares (the “Shares”) of the Issuer’s Class A Common Stock in exchange for capital stock in Platinum International Biotech Co., Ltd., a company organized under the laws of the Cayman Islands (“Platinum”), in connection with the acquisition of Platinum’s outstanding capital stock by the Issuer through a voluntary share exchange transaction (the “Exchange Transaction”) with the shareholders of Platinum (the “Selling Shareholders”), including the Reporting Person, pursuant to an Agreement and Plan of Share Exchange, dated as of January 14, 2021, by and among the Issuer, Platinum, Yubo International Biotech (Beijing) Co. Ltd., a company organized under the laws of the People’s Republic of China, and the Selling Stockholders (the “Exchange Agreement”). The Exchange Agreement was filed with the Securities and Exchange Commission on January 14, 2021 on a Current Report on Form 8-K. The Exchange Transaction closed on January 14, 2021.

 

Item 4. Purpose of the Transaction

 

The Reporting Person received the shares of Class A Common Stock in connection with the Exchange Transaction described in Item 3 above.

 

Subject to on-going evaluation, except as set forth above, the Reporting Person has no current plans or proposals which relate to or would result in any of the following:

 

(a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

 

(b) An extraordinary corporate transaction, such as a merger, reorganization, or liquidation, involving the Issuer or any of its subsidiaries;

 

(c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

 

(d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

 

 

 

CUSIP No. 988366100

Page 4 of 5

 

(e) Any material change in the present capitalization or dividend policy of the Issuer;

 

(f) Any other material change in the Issuer’s business or corporate structure, including but not limited to, if the Issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by Section 13 of the Investment Company Act of 1940;

 

(g) Changes in the Issuer’s charter, bylaws, or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person;

 

(h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

 

(i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or

 

(j) Any action similar to any of those enumerated above.

 

Item 5. Interest in Securities of the Issuer

 

(a) The Reporting Person beneficially own 24,967,800 shares of Class A Common Stock, which represents 21.1% of the issued and outstanding shares of Class A Common Stock of the Issuer.

 

(b) The Reporting Person has sole power to vote and sole power to dispose of 24,967,800 shares of Class A Common Stock.

 

(c) No transactions in the Issuer’s capital stock were effected during the past 60 days by the Reporting Person except as set forth in Item 3 above.

 

(d) Not applicable.

 

(e) Not applicable.

 

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

 

Reference is made to the Exchange Transaction described in Item 3 above.

 

Item 7. Material to be Filed as Exhibits

 

The Agreement and Plan of Share Exchange is hereby incorporated by reference to Exhibit 2.1 of the Issuer’s Current Report on Form 8-K filed on January 14, 2021.

 

 

  

CUSIP No. 988366100

Page 5 of 5

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, the Reporting Person hereby certifies that the information set forth in this Schedule 13D is true, complete, and correct.

 

	BOAO BIOTECH LIMITED
Dated:  January 20, 2021	By:	/s/ Yulin Cao
		Name: Yulin Cao
		Title: Director